VEGFA and epistaxis: In addition, TKIs showed a differential effect on skin and intestinal AVMs [40] and topical nasal spray of Bevacizumab (Avastin®), a recombinant, humanized VEGF antibody, did not improve epistaxis severity in the comparison to placebo treated patients [41, 42].